

1999/12/27 TW

UK Patent Application GB 2 164 336 A

(43) Application published 19 Mar 1986

(21) Application No 8520924

(22) Date of filing 21 Aug 1985

(30) Priority data


(31) 22383
21460(32) 22 Aug 1984
5 Jul 1985

(33) IT

(71) Applicant
Glaxo SpA (Italy),
Via A. Fleming 2, Vérone, Italy(72) Inventors
Claudio Semeraro,
Dino Micheli,
Daniele Pieraccioli,
Giovanni Gaviragli,
Allan David Borthwick(74) Agent and/or Address for Service
Elkington and Fife, High Holborn House, 52/54 High
Holborn, London WC1V 6SH(51) INT CL⁴
C07D 211/90 A61K 31/44(52) Domestic classification
C2C 1175 1177 1531 200 215 220 221 225 226 22Y 250
251 25Y 302 305 30Y 364 366 367 368 36Y 37X 43X 490
491 624 634 648 652 658 65X 66X 678 802 80Y AA BL
U1S 2415 C2C(56) Documents cited
None(58) Field of search
C2C

(54) 4-Aryl-1,4-dihdropyridine-3,5-dicarboxylate derivatives

(57) Compounds of formula



(wherein

 R_1 and R_4 independently represent a C_{1-4} alkyl group; R_2 and R_3 independently represent a C_{1-6} straight or branched alkyl chain which may be interrupted by an oxygen atom; R_5 represents a straight or branched chain C_{1-13} alkyl group or a C_{5-8} cycloalkyl group which may be substituted by a C_{1-3} alkyl substituent) reduce intracellular calcium ion concentration by limited transmembranal calcium ion influx and thus may be useful for the treatment of cardiovascular disorders such as *hypertension*.Intermediates of formula (I) are disclosed wherein R_5 is hydrogen.

GB 2 164 336 A

SPECIFICATION


Heterocyclic derivatives

5 This invention relates to novel heterocyclic derivatives which have an effect on the transmembranal influx of calcium ions into the cells of cardiac and smooth muscle, to processes for the preparation thereof, to pharmaceutical compositions containing them and to their use in therapeutics.

The role of intracellular calcium ions in the control of the contractile system of cardiac and smooth muscle is well known. Furthermore it has been established that compounds which limit the intracellular 10 calcium ion concentration by preventing or reducing the transmembranal calcium ion influx in cells of the contractile system of cardiac and smooth muscle are useful in the treatment of cardiovascular disorders.

We have now found a new group of compounds which reduce intracellular calcium ion concentration by limiting transmembranal calcium ion influx and thus may be useful for the treatment of cardiovascular 15 disorders such as hypertension, angina pectoris, myocardial ischaemia, congestive heart failure, cerebral vascular and peripheral disorders.

The invention thus provides for compounds of the general formula (I).



wherein

30 R_1 and R_4 independently represent a C_{1-4} alkyl group;
 R_2 and R_3 independently represent a C_{1-6} straight or branched alkyl chain which may be interrupted by an oxygen atom;

R_5 represents a straight or branched chain C_{1-13} alkyl group or a C_{5-8} cycloalkyl group which may be substituted by a C_{1-3} alkyl substituent;

35 The compounds represented by formula (I) can exist in more than one isomeric and/or enantiomeric form and the invention includes all such isomers, enantiomers and mixtures thereof. Thus the group $-CH=CHCO_2R_5$ in compounds of formula (I) can exist in the cis (Z) or the trans (E) configuration and the invention includes both isomers and mixtures thereof.

Examples of suitable groups for R_2 and R_3 independently include C_{1-4} straight or branched alkyl such as 40 methyl, ethyl, isopropyl, isobutyl, t-butyl or C_{1-4} alkyl (such as methyl, ethyl or n-propyl) substituted by a C_{1-3} alkoxy e.g. methoxy or propoxy group.

When the group R_5 represents a C_{1-13} alkyl group this may for example include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec butyl, tert butyl, pentyl, isopentyl, neopentyl, hexyl, 2,6-dimethyl-4-heptyl, octyl and tridecyl groups. When R_5 represents a cycloalkyl group, conveniently this represents cyclopentyl, cyclohexyl and cycloheptyl, which cycloalkyl groups may be substituted by a C_{1-3} alkyl group e.g. a 45 methyl group.

Preferred compounds of formula (I) are those in which the group $CH=CHCO_2R_5$ exists in the (E) configuration.

Preferred meanings for the groups R_1 and R_4 independently include ethyl or more particularly methyl. 50 R_2 and R_3 preferably independently represent C_{1-4} alkyl e.g. methyl, ethyl, isopropyl or isobutyl or ethyl substituted by C_{1-3} alkoxy e.g. methoxy or propoxy.

R_5 preferably represents C_{3-6} straight or branched alkyl such as isopropyl, tert butyl, 2,6-dimethyl-4-heptyl or octyl, or C_{5-8} cycloalkyl e.g. cyclopentyl or cyclohexyl which may be substituted by a methyl group.

A particularly preferred class of compounds of the invention are those of formula I wherein R_1 and R_4 55 represent methyl, R_2 and R_3 independently represent methyl, ethyl, isopropyl, isobutyl, propoxyethyl or methoxyethyl and R_5 represents C_{2-8} alkyl, more particularly isopropyl, tert butyl, 2,6-dimethyl-4-heptyl or octyl, or a cyclohexyl group which may be substituted by a methyl group.

Within this particularly preferred class of compounds those where R_5 represents a tertiary butyl group are especially preferred.

60 A particularly preferred compound according to the invention is 4-(2-(3-(1,1-dimethylethoxy)-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, diethyl ester and more especially the E isomer thereof.

Other preferred compounds according to the invention are 4-(2-(3-(1,1-dimethylethoxy)-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, 3-methyl ester, 5-(2-methylpropyl) 65 ester;

5

10

15

15

20

25

30

35

40

45

50

55

60

65

4-(2-(3-(1,1-dimethylethoxy)-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, dimethyl ester;
 4-(2-(3-(1,1-dimethylethoxy)-3-oxo-1-propenyl)phenyl-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, 3-methyl ester 5-ethyl ester;

5 and more particularly the E isomers thereof.

The compounds of the invention limit intracellular ion concentrations by preventing or reducing the transmembranal calcium ion influx in cells. Thus for example the compounds limit or inhibit the effect of calcium ions on the tone of depolarised vascular smooth muscle.

The antihypertensive activity of the compounds of the invention was demonstrated by intravenous and/or oral administration of the compound to male spontaneously hypertensive rats. In these tests compounds of the invention and more especially the specific compounds named above have been found to have a particularly advantageous profile of activity including a relatively long duration of action.

The compounds of the invention are thus of interest in the treatment of hypertension. They are also potentially useful for the treatment of other cardiovascular disorders including angina pectoris, myocardial ischaemia, congestive heart failure, cerebral vascular and peripheral disorders. They may be formulated in a conventional manner with one or more pharmaceutical carriers.

15 Thus a further aspect of the invention includes pharmaceutical compositions of the compounds of formula (I) formulated for oral, sub lingual, transdermal, parenteral or rectal administration.

For oral administration the pharmaceutical composition may take the form of for example tablets, which may be film or sugar coated, capsules, powders, granules, solutions including syrups, or suspensions prepared by conventional means with acceptable excipients. For sub lingual administration the composition may take the form of tablets or lozenges formulated in conventional manner.

20 For parenteral administration the compounds of formula (I) may be given as a bolus injection or by continuous infusion. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. For administration by injection these may take the form of a unit dose presentation or as a multidose presentation preferably with an added preservative.

25 Alternatively for parenteral administration the active ingredient may be in powder form for reconstitution with a suitable vehicle.

30 The compounds of formula (I) may be formulated as ointments and creams for transdermal administration and as suppositories or retention enemas for rectal administration.



A proposed daily dosage of active compound of the invention for the treatment of man is in the range of 0.005mg to 50mg for example 0.01mg to 20mg, which may conveniently be administered in one or more doses. The precise dose employed will depend on the age and condition of the patient as well as 35 the route of administration.

35 For oral use the compounds of the invention are conveniently administered to the human patient at a dose in the range 0.01 to 50mg, more preferably 0.1 to 20mg per day. For parenteral use the compounds of the invention are conveniently administered at a dose in the range of 0.005 to 1mg, more preferably 0.01-0.5mg per day.



40 For oral use the compound is preferably administered twice or more particularly once a day.

45 Methods for preparing the compounds of formula (I) are described below and for the intermediates described below R₁, R₂, R₃, R₄, and R₅, have the meanings defined above for compounds of formula (I) or are such groupings in a protected form.

Thus compounds of formula (I) and more particularly the E isomers thereof, may be prepared by reaction 45 the α,β-unsaturated ketone (II) with the aminoester (III). The reaction is conveniently carried out in a solvent such as an alkanol, e.g. ethanol or isopropanol and preferably with heating e.g. 40-150°C.



5



5

10 In a modification of this process for preparing compounds of formula (I), the aldehyde (IV) may be reacted with a mixture of the aminoester (III) and the ketoester (V) under the conditions previously described for the reaction of the α,β -unsaturated ketone (II) with the aminoester (III).

Compounds of formula (I) and in particular the E isomers thereof in which R₁ and R₄ are the same and R₂ and R₃ are the same may be prepared by reacting the aldehyde (IV) with the aminoester (III) in the presence of a suitable acid catalyst. Examples of suitable acid catalysts include organic acids such as oxalic acid, alkanoic acids e.g. acetic acid or haloalkanoic acids such as trichloroacetic acid or trifluoroacetic acid or pyridinium salts thereof, or a sulphonic acid such as an alkanesulphonic acid e.g. methanesulphonic acid or an arylsulphonic acid e.g. benzenesulphonic acid or p-toluenesulphonic acid or a tetrahaloboric acid such as tetrafluoroboric acid. The reaction is preferably carried out in the presence of a solvent and at a temperature within the range of -70° to 30°C preferably -30° to 10°C. Suitable solvents for the reaction include aprotic solvents such as hydrocarbons, e.g. hexane or cyclohexane, acetonitrile or ethers such as tertiary butyl methyl ether, dioxan or tetrahydrofuran, or protic solvents such as an alkanol e.g. methanol, ethanol, propanol, isopropanol or butanol.

Compounds of formula (I) and more particularly the E isomers thereof in which R₁ and R₄ are the same and R₂ and R₃ are the same may also be prepared by reacting the aldehyde (IV) with the ketoester (V) and ammonium acetate. This reaction is conveniently carried out in a solvent such as pyridine with heating at 50 - 120°C, conveniently at reflux.


In a further process of the invention compounds of formula (I) may be prepared by esterifying the corresponding acid of formula (I) in which R₅ is hydrogen. Thus in one embodiment of this process compounds of formula (I) may be prepared by treating a compound of formula (I) in which R₅ is hydrogen with an alkylating agent R₂X where R₂ is as defined in formula (I), and X is a leaving group such as chloride, bromide, iodide or mesylate. The reaction is preferably carried out in the presence of a base such as an alkali or alkaline earth metal carbonate e.g. potassium carbonate in a polar aprotic solvent such as dimethylformamide or dimethylsulphoxide optionally with heating. Thus for example the reaction may be carried out a temperature within the range 10-100°.

In a further embodiment of this process compounds of the invention may be prepared from the corresponding carboxylic acid of formula (I) in which R₅ is hydrogen, via an activated derivative thereof such as a mixed anhydride, by reaction with an appropriate alcohol R₅OH, where R₅ is as defined in formula (I), or the corresponding alkoxide thereof.

40 The compounds of formula (I) wherein R₅ represents hydrogen may be prepared by hydrolysis of a compound of formula (I) wherein R₅ represents a tertiary butyl group. The hydrolysis may be carried out using hydrogen bromide in acetic acid, in the presence of a solvent such as dichloromethane. Preferably the reaction is carried out at low temperatures e.g. -78° - 35°C.

In yet another process of the invention the E isomers of compounds of formula (I) may be prepared by 45 treating a compound of formula (VI)

50



50

55

(where Hal represents a bromine or iodine atom) with an acrylic ester $\text{CH}_2=\text{CHCO}_2\text{R}_6$ (VII), in the presence of a catalytic amount of a palladium salt such as palladium acetate, in the presence of a suitable organic base such as a trialkylamine e.g. triethylamine or tri-n-butylamine. The reaction is also preferably carried out in the presence of a triarylphosphine such as tri-o-tolyphosphine, or more preferably, triphenylphosphine.

The reaction is conveniently carried out in a suitable solvent such as xylene or t-butyl acetate, or more conveniently in dimethylformamide or in a mixture of solvents e.g. xylene/dimethylformamide, preferably 65 with heating. The reaction mixture is preferably heated within the temperature range of 80°C to 150°C,

55


60

65

- more preferably at 100°C to 110°C.

The carboxylic acids represented by the compounds of formula (I) wherein R₅ represents hydrogen are new compounds and useful chemical intermediates for preparing the compounds of formula (II) and represent a further feature of the invention.

5 Compounds of formula (IV) may be prepared by reacting the bis aldehyde (VIII) with the triphenylphosphorane (IX) in solvent such as methylene chloride or toluene.



15 Compounds of formula (IV) may also be prepared by reacting a 2-halobenzaldehyde (X)




(where Hal represents a bromine or iodine atom) with an acrylic ester (VII). The reaction takes place under the conditions previously described for the reaction between the compound of formula (VI) and the acrylic ester (VII).

The compounds of formula (VI) may be prepared by reacting the 2-halobenzaldehyde (X) with the amine ester (III) and/or the ketoester (V) according to the conditions described above for the reaction between the compound of formula (IV) and the amine ester (III) and/or the ketoester (V).

30 The compounds of formulae (III), (V), (VII), (VIII), (IX) and (X) are either known compounds or may be made by analogous processes to those used for known compounds.


Compounds of formula (I) in which the group $-\text{CH}=\text{CHCO}_2\text{R}_5$ is in the cis (Z) configuration may be prepared by irradiating a solution of the corresponding trans (E) isomer. Thus when a solution of the E isomer in dichloromethane under an atmosphere of nitrogen is exposed to daylight a mixture of the E and Z isomers are obtained and these may be separated by standard techniques such as fractional crystallisation and/or chromatography.

Compounds of formula (I) may also be prepared from the reaction of the compound (XI) with the phosphorane (IX) in a suitable solvent such as dichloromethane, tetrahydrofuran or toluene. Preferably the reaction is carried out with heating for example 40-120°C, conveniently at reflux.



The intermediate (XI) may be prepared by aqueous acid hydrolysis of the corresponding acetal (XII; in which R₁ represents an alkyl group) or by reaction with a compound

55 The compound of formula (XII) may be prepared from the aldehyde (XIII) by reaction with a compound of formula (III) and/or (V) under the conditions described above for preparing compounds of formula (I) from the intermediate (IV). The intermediate (XIII) may be prepared from the bromobenzene derivative (XIV) by reaction with butyl lithium in solvent followed by addition of dimethylformamide.



The following examples illustrate the invention. Throughout the examples reference to t.l.c. means thin layer chromatography on Merck (RTM) silica gel 60F-254. All temperatures refer to °C.

Intermediate 1

5 1a. *(E)-3-(2-Formylphenyl)-2-propenoic acid, 1,1-dimethyl ethyl ester*

5

A solution of triphenylphosphoranylidene acetic acid 1,1-dimethylethyl ester (54.7g) in dry dichloromethane (100ml) was added to a solution of ortho phthaldehyde (19.3g) in dry dichloromethane at 0°C in 15 minutes. The solvent was evaporated and the oil taken up with diethyl ether. The solid triphenylphosphine oxide was filtered, washed with ether and the filtrate evaporated to dryness to give a yellow oil 10 (36g), which was eluted on a silica gel column (petrol ether/diethyl ether, 7 : 3), to give *the title compound* as a colourless oil (21.4g).

10

T.I.c. (Petrol ether/diethyl ether, 1 : 1) Rf = 0.45.

15 1b. In a similar manner (E)-3-(2-formylphenyl)-2-propenoic acid, ethyl ester (12g) was prepared from o-phthaldehyde (13.4g) and triphenylphosphoranylidene acetic acid ethyl ester (34.8g).

15

T.I.c. (Petrol ether/diethyl ether, 1 : 1) Rf = 0.40.

Intermediate 2

2-(Diethoxymethyl)bromobenzene

20 20 A mixture of 2-bromobenzaldehyde (33.2g), triethyl orthoformate (29g) and powdered ammonium chloride (0.379g) in ethanol (30ml) was stirred for eight hours at room temperature. The resulting suspension was filtered and the filtrate evaporated. The resulting yellow oil was distilled at reduced pressure to give *the title compound* (31g). b.p. 63°C 0.3 mm Hg. T.I.c. (Petrol/diethyl ether, 6:1) Rf = 0.6.

20

25 25 *Intermediate 3*

2-(Diethoxymethyl)benzaldehyde

To a solution of tetrahydrofuran (250ml) and ether (250ml) was added a 1.2M solution of butyl lithium in hexane (160ml). The mixture was stirred and cooled to -70°C and then Intermediate 2 (50g) was added dropwise. After the addition the mixture was stirred at -70° for 30 minutes and then a solution of 30 dimethylformamide (165ml) in tetrahydrofuran (75ml) was added slowly dropwise keeping the temperature at -65°. A saturated aqueous solution of ammonium chloride (150ml) was added, the organic phase separated and the aqueous phase extracted with ether (2×70ml). The combined organic phase was dried ($MgSO_4$) and evaporated. The resulting brown oil was distilled at reduced pressure to give *the title compound* (30g) as a white waxy solid. b.p. 87°C 0.9 mm Hg. T.I.c. (Petrol/diethyl ether, 7 : 3) Rf = 0.6.

30

35

35

Intermediate 4

4-(2-Formylphenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, diethyl ester

To a stirred solution of ethyl-3-aminocrotonate (9.3g) in glacial acetic acid (5ml) at 0° was added dropwise Intermediate 3 (5g). After two hours the reaction was poured into ethyl acetate (100ml) and shaken 40 with 10% hydrochloric acid. The organic phase was separated, dried ($MgSO_4$) and evaporated. The residual brown oil was purified by column chromatography (silica gel, dichloromethane/ethyl acetate 7:3) and crystallized from diethyl ether to give *the title compound* (0.200g) as a yellow solid. m.p. 172-173°. T.I.c. (Petrol/ethyl acetate, 7:3) Rf = 0.4.

40

45 45 *Intermediate 5*

4-(2-Carboxyethenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, diethyl ester

45

To a solution of the compound of Example 1 (10g) in dichloromethane (70ml), at -78°C was added slowly, a solution of HBr/CH₃COOH 33% in dichloromethane (70ml). The mixture was then warmed to -35°C and after 10 minutes poured into ice/water. The pH was adjusted at 6 and the mixture extracted 50 with ethyl acetate, washed with water and dried over Na₂SO₄. Evaporation of the solvent gave a solid which was recrystallized from petrol ether/ethyl acetate (1:1) to give *the title compound* as a white solid (6.5g). T.I.c. (CH₂Cl₂/CH₃CO₂C₂H₅/CH₃COOH, 8:2:1) Rf = 0.4 m.p. 175-178°.

50

Intermediate 6

55 55 6a. *2,6-Dimethyl-4-heptylmethanesulphonate*

55

A solution of methanesulphonyl chloride in diethyl ether was added dropwise to a solution of 2,6-dimethyl-4-heptanol and triethylamine in ether at 0°C. The mixture was then stirred for 2 hrs at room temperature, then poured into water and extracted with ether. The organic phase was washed with dilute hydrochloric acid, then water and dried over Na₂SO₄. Evaporation of the solvent gave *the title compound* 60 (2.6g) as a colourless oil. T.I.c. (Ethyl acetate/cyclohexane, 4:6). Rf. = 0.55.

60

Similarly prepared was:-

6b. *2-Methylcyclohexylmethanesulphonate*

T.I.c. (methylene chloride/Ethyl acetate, 7:3) Rf. = 0.75. from methanesulphonyl chloride and 2-methylcyclohexane

65

*Intermediate 7**4-(2-Bromophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridine-carboxylic acid, diethyl ester*

(a) A solution of 2-bromobenzaldehyde (83.7g) in absolute ethanol (1350ml) was cooled to -10° under stirring. To the solution trifluoroacetic acid (108g) was added quickly followed by a solution of ethyl 3-amino crotonate (146g) in ethanol (750ml) added dropwise during 1 hour. Stirring was continued for a further 1 hour at -10° and the mixture was then added dropwise to a 0.3% solution of hydrochloric acid (7000ml) under vigorous stirring. The solid was collected by filtration, washed with water and petroleum ether and dried *in vacuo* at 60° to give the *title compound* (156g). m.p. 142-143°. T.I.c. (ethyl acetate/petroleum ether, 8:2) Rf = 0.5

(b) A solution of 2-bromobenzaldehyde (10.8g), ethyl 3-amino crotonate (9.36g) and ethyl acetoacetate (9.12g) in absolute ethanol (50ml) was heated at reflux for 15 hours. The mixture was then cooled, diluted with absolute ethanol (250ml) and added dropwise to a 0.2% solution of hydrochloric acid (2000ml) under vigorous stirring. The solid was collected by filtration, washed with petroleum ether (150ml) and dried *in vacuo* to give the *title compound* (19.3g) m.p. 142-143°.

dried *in vacuo* to give the *title compound* (19.3g) m.p. 142-143°.

*Intermediate 8**4-(2-Iodophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridine-carboxylic acid, diethyl ester*

Following the procedure in Intermediate 7(a) 2-iodobenzaldehyde (46.4g) and ethyl 3-amino crotonate (73g) gave the *title compound* (54.8g) m.p. 178°. T.I.c. (dichloromethane/ethyl acetate, 9:1) Rf = 0.5.

*Intermediate 9**2-(2-{3-(1,1-Dimethylethoxy)-3-oxo-1-propenyl}phenyl)-methylene-3-oxo-butanoic acid, methyl ester*

A solution of piperidine (0.11g) and acetic acid (0.078g) in isopropanol (1ml) was added to a solution of 3-(2-formylphenyl)propenoic acid 1,1-dimethylethyl ester (5.2g) and methyl acetoacetate (2.55g) in isopropanol (15ml). The mixture was stirred at 60°C for 1h, then the solvent was evaporated and the residue taken up with ether (100ml). The solution was washed with 1N HCl, water, with saturated bicarbonate solution, then water again and dried over Na₂SO₄. Evaporation of the solvent gave an oil which was purified by column chromatography (gradient Petrol/Ether, 7:3 - 1:1) to give the *title compound* as a pale oil (4.2g; mixture E/Z isomers).

Example 1
(E)-4-(2-{3-(1,1-Dimethylethoxy)-3-oxo-1-propenyl}phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, diethyl ester

Ethyl 3-amino crotonate (24g) was added to a solution of Intermediate 1a (21.4g) in acetic acid, at room temperature. The red solution was stirred at room temperature for 5hrs, then poured into water and extracted with ethyl acetate. The organic phase was washed with 5% aqueous sodium bicarbonate solution, then with water and dried over Na₂SO₄. Evaporation of the solvent gave a dark oil, which was eluted on a silica gel column (CH₂Cl₂/Ethyl acetate, 9:1). The *title compound* was obtained as a white solid (3.6g) and recrystallized from ethyl acetate, m.p. 173-175°C. T.I.c. (methylene chloride/Ethyl acetate, 9:1) Rf = 0.4

Example 2
4-(2-{3-(1,1-Dimethylethoxy)-3-oxo-1-propenyl}phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, diethyl ester

To a solution of Intermediate 4 (0.1g) in dichloromethane (0.5ml) was added triphenylphosphoranylidene acetic acid 1,1-dimethylethyl ester (0.1g) in dichloromethane (0.5ml) at room temperature. After 12 hours reflux in dichloromethane, tetrahydrofuran was added and refluxing continued for 12 hours. Then toluene was added and the mixture refluxed for a further 5 hours. The mixture was evaporated and the residue purified by column chromatography and crystallized from petrol to give the *title compound* (120mg) as a mixture of E and Z isomers.

Example 3
(E)-4-(2-{3-Ethoxy-3-oxo-1-propenyl}phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, diethyl ester

Ethyl 3-amino crotonate (13g) was added to a solution of Intermediate 1b (10.2g) in acetic acid (150ml), at room temperature. The red solution was stirred at room temperature for 3 hrs., then poured into water and extracted with ethyl acetate. The organic phase was washed with 5% aqueous sodium bicarbonate solution, then with water and dried over Na₂SO₄. Evaporation of the solvent gave a dark oil (20g), which was eluted on a silica gel column (CH₂Cl₂/Ethyl acetate, 7:3). The *title compound* was obtained as a white solid (4.5g) and recrystallized from petrol/ether/diethyl ether (9:1); m.p. 130-131°C; T.I.c. (methylene chloride/Ethyl acetate, 8:2) Rf = 0.50.

Example 4
4a. *(E)-4-(2-{3-(1,1-dimethylethoxy)-3-oxo-1-propenyl}-phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridine-di-*
65 *carboxylic acid 3-methyl ester, 5-ethyl ester*

Intermediate 1a (0.5g), ethyl 3-aminocrotonate (0.27g) and methyl acetoacetate (0.24g) in ethanol were refluxed for 14 hours. The solvent was then evaporated and the crude oil was eluted on a silica gel column (diethyl ether/petrol ether 7:3) to yield the *title compound* as a pale yellow solid (0.25g), m.p. 165-167°C (petrol ether). T.I.c. (Diethyl ether/petrol ether, 9:1) Rf = 0.3

5 Similarly prepared were:-

5

4b. (*E*)-4-(2-(3-(1,1-dimethylethoxy)-3-oxo-1-propenyl)-phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid 3-methyl ester, 5-(2-methylpropyl) ester m.p. 147° - 149° (petrol ether)
T.I.c. (Petrol ether/ethyl acetate 6:4) Rf = 0.35

10 From Intermediate 1a, methyl 3-aminocrotonate and 2-methylpropyl acetoacetate

10

4c. (*E*)-4-(2-(3-(1,1-dimethylethoxy)-3-oxo-1-propenyl)-phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, 3-(1-methylethyl) ester, 5-(2-methoxyethyl) ester m.p. = 156°-157°C (petrol ether)
T.I.c. (ethyl acetate/cyclohexane, 1:1) Rf = 0.35

15 From Intermediate 1a, 1-methylethyl 3-aminocrotonate and 2-methoxyethyl acetoacetate

15

4d. (*E*)-4-(2-(3-(1,1-dimethylethoxy)-3-oxo-1-propenyl)-phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, dimethyl ester m.p. = 158°-162° (petrol ether/diethyl ether, 100:1). T.I.c. (petrol/ethyl acetate, 6:4) RF = 0.25

20 From Intermediate 1a, methyl 3-aminocrotonate and methyl acetoacetate

20

4e. (*E*)-4-(2-(3-(1,1-dimethylethoxy)-3-oxo-1-propenyl)-phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, bis-2-n-propoxyethyl ester
m.p. = 115-116 (petrol ether)

25 T.I.c. (ethyl acetate/cyclohexane 1:1) Rf = 0.40

25

From Intermediate 1a, n-propoxyethyl 3-aminocrotonate and n-propoxyethyl acetoacetate

4f. (*E*)-4-(2-(3-Ethoxy-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl (1,1-dimethyl)ethyl ester

30 From Intermediate 1b, 3-oxobutanoic acid ethyl ester and 3-aminobutenoic acid 1,1-dimethylethyl ester.

30

Example 5

5a. (*E*)-4-(2-(3-Octyloxy-3-oxo-1-propenyl)phenyl)-1,4-di-hydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, di-ethyl ester

35 A suspension of the Intermediate 5 (0.5g), octyl bromide (0.38g) and potassium carbonate (10g) was stirred at room temperature for 20 hrs. The mixture was poured into water and extracted with ethyl acetate, washed thoroughly with water and dried over Na₂SO₄.

35

Evaporation of the solvent gave an oil which was triturated with petrol ether and recrystallized from petrol ether to give the *title compound* as a white solid (0.3g), m.p. 110-112°. T.I.c. (methylene chloride/

40 ethyl acetate, 9:1) Rf = 0.5

40

Similarly were prepared:-

5b. (*E*)-4-(2-(3-Methoxy-3-oxo-1-propenyl)phenyl)-1,4-di-hydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, diethyl ester m.p. 138-140°C (petrol ether). T.I.c. (methylene chloride/Ethyl acetate 8:2) Rf = 0.40

45 From Intermediate 5 and methyl bromide.

45

5c. (*E*)-4-(2-(3-(1-Methylethoxy)-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, diethyl ester m.p. 145-147°C (petrol ether)

T.I.c. (methylene chloride/Ethyl acetate, 8:2) Rf = 0.45

50 From Intermediate 5 and 1-methylethyl bromide.

50

5d. (*E*)-4-(2-(3-(2-Methylpropyloxy)-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, diethyl ester m.p. 172-174°C (petrol ether). T.I.c. (methylene chloride/Ethyl acetate, 8:2) Rf = 0.55

55 From Intermediate 5 and 2-methylpropylbromide.

55

5e. (*E*)-4-(2-(3-Cyclohexyloxy-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid diethyl ester m.p. 175-177°C (petrol ether)

T.I.c. (methylene chloride/Ethyl acetate, 9:1) Rf = 0.40

60 From Intermediate 5 and cyclohexyl bromide.

60

5f. (*E*)-4-(2-(3-Tridecyloxy-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, diethyl ester m.p. = 87-89°C. T.I.c. (Petrol ether/ethyl acetate, 6:4) Rf. = 0.40.

From Intermediate 5 and tridecyl bromide at room temperature

5g. (*E*)-4-(2-(3-Cycloheptyloxy-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, diethyl ester m.p. = 192-194°C. T.I.c. (methylene chloride/Ethyl acetate, 8:2) Rf. = 0.45
From Intermediate 5 and cycloheptyl bromide

5 5h. (*E*)-4-(2-(3-Cyclopentyloxy-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, diethyl ester m.p. = 182-184°C. T.I.c. (Ethyl acetate/cyclohexane, 1:1) Rf. = 0.42
From Intermediate 5 and cyclopentyl bromide.

Example 6

10 10 (*E*)-4-(2-(3-Octyloxy-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid diethyl ester

A suspension of the intermediate 5 (0.1g), octyl methane-sulphonate (0.077g) and potassium carbonate (2g) in dimethylformamide (5ml) was stirred at room temperature for 20 hrs. The mixture is poured into water and extracted with ethyl acetate, washed thoroughly with water and dried over Na₂SO₄. Evaporation of the solvent gave an oil which was triturated with petrol ether and recrystallized from petrol ether to give the *title compound* as a white solid, (0.04g). m.p. 110-112°C. T.I.c. (methylene chloride/Ethyl acetate, 9:1) Rf = 0.5

Example 7

20 20 (*E*)-4-(2-(3-(1,1-Dimethylethoxy)-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, diethyl ester

A suspension of the intermediate 5 (0.2g) and potassium carbonate (0.07g) in N,N-dimethylformamide (5ml) was treated with tert-butyl bromide (0.14g) and stirred at room temperature for 20 hrs. The mixture was poured into water and extracted with ethyl acetate, washed thoroughly with water and dried over Na₂SO₄. Evaporation of the solvent gave an oil which was crystallized from petrol ether to give the *title compound* as a white solid (0.005g) m.p. 173-175°C.

Example 8

30 30 (*Z*)-4-(2-(3-(1,1-Dimethylethoxy)-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, diethyl ester

A solution of the compound of Example 1 (1g) in dichloromethane (250ml) was deoxygenated with a stream of nitrogen for 3 min., then left standing, under an atmosphere of nitrogen, in daylight for two weeks. The solution was then evaporated and the solid was recrystallized twice from petrol/diethyl ether (9:1). The white solid obtained (0.2g) was eluted 5 times on a silica gel plate (CH₂Cl₂) to obtain a colourless oil. Crystallization from petrol ether/diethyl ether (9:1) gave the *title compound* as a white solid (0.05g) m.p. 143-145°C. T.I.c. (methylene chloride/Ethyl acetate, 9:1) Rf = 0.40

Example 9

40 40 (*E*)-4-(2-(3-(2,6-Dimethyl-4-heptyloxy)-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, diethyl ester

A suspension of Intermediate 5 (2g), 2,6-dimethyl-4-heptylmethanesulphonate (1.6g) and potassium carbonate (40g) in dimethylformamide (30 ml) was stirred at 60°C for 12 hours. The mixture was poured into water and extracted with ethyl acetate, washed thoroughly with water and dried over Na₂SO₄. Evaporation of the solvent gave a crude oil (3g) which was eluted on a silica gel column (Diethyl ether/petrol ether, 8:2) to yield the *title compound* (0.66g) as a white solid. m.p. 49-52°C
T.I.c. (Petrol ether/Ethyl acetate, 6:4) Rf. = 0.45

Similarly prepared were:-

45 45 9b. (*E*)-4-(2-(3-(2-Methylcyclohexyloxy)-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, diethyl ester m.p. 165-166°C

T.I.c. (methylene chloride/Ethyl acetate, 8:2) Rf = 0.55.
From Intermediate 5 and 2-methylcyclohexyl-methanesulphonate.

50 50 (*E*)-4-(2-(3-(1,1-Dimethylethoxy)-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-diethyl-3,5-pyridinedicarboxylic acid diethyl ester

A solution of Intermediate 1a (3.2g) in ethanol (25ml) was cooled to 0°C and then trifluoroacetic acid (2ml) added, followed by a solution of ethyl-3-aminocrotonate (10g) in ethanol (25ml). The mixture was stirred at 0°C for 1 hr, then poured into water and neutralized with 10% sodium bicarbonate and extracted with ethyl acetate. The organic layer was washed with 10% hydrochloric acid then with water and dried over Na₂SO₄. Evaporation of the solvent gave an oil which was eluted on a silica gel column (gradient Ether/petrol, 3:7 - 7:3) to give the *title compound* (2g) as a pale yellow solid. m.p. = 154-155°C
T.I.c. (Petrol ether/Ethyl acetate, 1:1) Rf = 0.65.

Example 11

(E)-4-(2-(3-(1,1-Dimethylethoxy)-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, diethyl ester

(a) A mixture of the intermediate 7 (171.5g), tertiary butylacrylate (67.0g), tributylamine (97.6g), palladium acetate (0.94g) and triphenylphosphine (4.4g) in dimethylformamide (200ml) was heated at 110° for 24 hours under nitrogen. The mixture was then cooled, the catalyst removed by filtration and the organic solvent was evaporated to dryness. The residue was dissolved in acetone (700ml) and the resulting solution was added dropwise to a 0.5% solution of hydrochloric acid (8000ml) under vigorous stirring. The solid was collected by filtration, washed with water and petroleum ether and dried *in vacuo* at 10 60° to give a yellow solid. The solid was recrystallised twice from ethyl acetate (500ml) to give the title compound (100g) m.p. 174-175°.

T.I.C. (dichloromethane/ethyl acetate, 8:2) R_f = 0.48.

(b) In a similar manner the intermediate 8 (91g) and tertiary butylacrylate (33g) gave the *title compound* (46g).

15 *Example 12* 15
 (E)-4-(2-(3-(1,1-Dimethylethoxy)-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid diethyl ester
 A solution of ethyl 3-aminocrotonate (19.5g) in absolute ethanol (75ml) was added to a mixture of 20 (E)tert-butyl-2-formyl-cinnamate (11.6g) and trifluoroacetic acid (11.4g) in absolute ethanol (90ml) at -10° to 0°C. The mixture was aged for 1.5h within this temperature range and then 8% aqueous sodium bicarbonate (150ml) was added. The product was extracted with tert-butyl methyl ether (3×200ml), the combined extracts washed with water (2×150ml) and dried (MgSO₄). Filtration followed by evaporation of solvent gave an oil which was triturated with petroleum ether (50ml) then filtered to give a granular 25 solid. Crystallisation from ethyl acetate (30ml) to give the *title compound* (8.5g). M.p. 174-175°. 25

Example 13

(E)-4-(2-(3-(1,1-dimethylethoxy)-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, methyl ethyl ester

30 Ethyl 3-aminocrotonate (1.13g) and the intermediate 9 (2.9g) in ethanol (20ml) were heated under reflux for 13 hr. The solvent was evaporated and the residual oil was purified by column chromatography (gradient petrol/Ethyl acetate, 7:3 - 1:1) to give the *title compound* (0.42g) as a white solid, m.p. = 165-167°C. 30

*Example 14*35 *Pharmaceutical compositions* 35

(a) TABLETS

	(I)	mg/tablet	
40	Active ingredient	1	40
	Polyvinylpyrrolidone (PVP)	20	
	Lactose B.P.	127	
	Magnesium stearate B.P.	2	
45	Compression weight	150	45

The drug is granulated by a solution of PVP in ethanol, blended with the excipients and compressed using punches to suit.

	(II)	mg/tablet	
50	Active ingredient	1	50
	Microcrystalline cellulose BPC	40	
	Lactose B.P.	100	
55	Sodium carboxymethylcellulose	8	55
	Magnesium stearate B.P.	1	
	Compression weight	150	

60 The drug is sieved through a suitable sieve, blended with the excipients and compressed using punches to suit. Tablets of other strengths may be prepared by altering the compression weight and using punches to suit. The tablets may be film coated with suitable film forming materials, eg methyl cellulose, ethyl cellulose or hydroxypropylmethyl cellulose, using standard techniques. Alternatively the tablets may be sugar 65 coated. 60

(b) SOFT GELATIN CAPSULES

mg/capsule

5	Active ingredient Polyethylene glycol (PEG) 400	1 199 —	5
		Fill weight	200

The drug is dissolved in PEG 400 with stirring and the mix is filled into soft gelatin capsules using a suitable filling machine. Other doses may be prepared by altering the fill weight and if necessary changing the capsule size to accommodate the change in fill weight.

10


In the above pharmaceutical examples the active ingredient refers to one or more compounds of the general formulae I but is preferably 4-(2-(3-(1,1-dimethylethoxy)-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridine dicarboxylic acid diethyl ester, and more especially the E isomer thereof.

15

15 CLAIMS

1. Compounds of the general formula (I).

20



30

30 wherein
R₁ and R₄ independently represent a C₁₋₄ alkyl group;
R₂ and R₃ independently represent a C₁₋₆ straight or branched alkyl chain which may be interrupted by an oxygen atom;

35

R₅ represents a straight or branched chain C₁₋₁₃ alkyl group or a C₅₋₈ cycloalkyl group which may be substituted by a C₁₋₃ alkyl group;

40

2. Compounds as claimed in Claim 1 in which R₁ and R₄ independently represent methyl or ethyl groups.

45

3. Compounds as claimed in Claims 1 or 2 in which both R₁ and R₄ represent methyl.

50

4. Compounds as claimed in any of Claims 1 to 3 in which R₂ and R₃ independently represent a C₁₋₄ alkyl group, which may be substituted by a C₁₋₃ alkoxy group.

55

5. Compounds as claimed in any of Claims 1 to 4 in which R₂ and R₃ independently represent groups selected from methyl, ethyl, isopropyl, isobutyl, t-butyl, methoxyethyl or propoxyethyl.

60

6. Compounds as claimed in any of Claims 1 to 5 in which R₅ represents a C₃₋₉ straight or branched alkyl group or a C₅₋₇ cycloalkyl group which may be substituted by a C₁₋₃ alkyl group.

65

7. Compounds as claimed in any of Claims 1 to 6 in which R₅ represents an isopropyl, tertiary butyl, 2,6-dimethyl-4-heptyl, octyl or cyclohexyl group or a cyclohexyl group substituted by a methyl group.

70

8. Compounds as claimed in any of Claims 1 to 7 in which R₁ and R₄ represents a methyl group, R₂ and R₃ independently represent a methyl, ethyl, isopropyl, isobutyl, propoxyethyl or methoxyethyl group and R₅ represents an isopropyl, tert butyl, 2,6-dimethyl-4-heptyl, octyl or cyclohexyl group or a cyclohexyl group substituted by a methyl group.

75

9. Compounds as claimed in any of Claims 1 to 8 in which R₅ represents a tertiary butyl group.

80

10. 4-(2-(3-(1,1-Dimethylethoxy)-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid diethyl ester.

85

11. A compound selected from

90

55 4-(2-(3-(1,1-dimethylethoxy)-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, 3-methyl ester, 5-(2-methylpropyl)ester:

95

4-(2-(3-(1,1-dimethylethoxy)-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, dimethyl ester:

100

4-(2-(3-(1,1-dimethylethoxy)-3-oxo-1-propenyl)phenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid, 3-methyl ester 5-ethyl ester;

105

12. The E isomer of the compound as claimed in any of Claims 1 to 11.


110

13. A process for the preparation of a compound of general formula (I) as defined in claim 1 which process comprises:


115

(a) reacting a compound of formula (II) in which R₁, R₂ and R₅ have the meanings defined in claim 1 with the aminoester (III) in which R₃ and R₄ have the meanings defined in claim 1.

120




10 (b) reacting the aldehyde of formula (IV) with an aminoester of formula (III) and the ketoester of formula (V), in which the respective groups R_5 , R_6 , R_7 , R_8 , and R_9 have the meanings defined in claim 1.




(c) the preparation of compounds of formula (I) in which R₁ and R₄ are the same and R₂ and R₃ are the same by reacting the aldehyde (IV) with (1) the aminoester of formula (III) or (2) a ketoester of formula (V) in the presence of an ammonium salt.

(d) esterification of the corresponding acid of formula (I) in which R₁ represents hydrogen.

(e) the preparation of the E isomer of formula (I) by reacting a compound of formula (VI) in which R₁, R₂, R₃ and R₄ have the meanings defined in claim 1 and Hal represents bromine or iodine with an acrylic ester $\text{CH}_2=\text{CHCO}_2\text{R}_5$ (VII) in the presence of a palladium salt and an organic base.



(f) reacting a compound of formula (XII), in which R₁, R₂, R₃ and R₄ have the meanings defined in claim 1, with the triphenylphosphorane (IX) in which R₇ has the meaning given in claim 1.



(g) the preparation of the Z isomer of a compound of formula (I) by irradiating a solution of the corresponding E isomer of formula (I).

14. Pharmaceutical compositions comprising a compound as claimed in Claim 1 in association with a pharmaceutically acceptable carrier or diluent.

15. Compositions as claimed in Claim 14 in a form suitable for oral, sub lingual, transdermal, parenteral or rectal administration.

65 16. Composition as claimed in Claim 15 for oral administration in the form of a tablet or capsule. 65

17. Composition as claimed in Claim 16 containing a dose of 0.01 to 50mg of active ingredient.
18. A compound of formula (I) in which the groups R₁, R₂, R₃ and R₄ have the meanings given in Claim 1 and R₅ represents a hydrogen atom.

Printed in the UK for HMSO, D8818935, 1/86, 7102.

Published by The Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.